
| 2015 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2012 | |
| Criterium: | Position: |
| Overall Score: | 900-1000 |
| Networking Rank (Reputation): | 800-900 |
| Networking Rank (Reputation): | 800-900 |
Total number of projects: 6
As coordinator: 0
As participant: 6
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2018 | 0 | 5.931.669 | 239.630 | 1 | ||
| 2017 | 0 | 8.025.000 | 552.280 | 1 | ||
| 2015 | 0 | 5.972.496 | 405.000 | 1 | ||
| 2012 | 0 | 15.794.351 | 1.588.811 | 3 | ||
Total number of partners: 62
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 59
Frequent / Rare Partner Ratio: 0.05
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2018-01-01 | IMaging-based CUSTOMised EYE diagnostics | IMCUSTOMEYE | participant | 5.931.669 | 11 |
| 2017-09-01 | Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 | MACUSTAR | participant | 8.025.000 | 13 |
| 2015-05-01 | Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways | EYE-RISK | participant | 5.972.496 | 12 |
| 2012-12-01 | Orphan Drug for Acanthamoeba Keratitis | ODAK | participant | 4.050.255 | 6 |
| 2012-10-01 | European Consortium for the Study of a Topical Treatment of Neovascular Glaucoma | STRONG | participant | 5.745.334 | 8 |
| 2012-03-01 | European Consortium for the Early Treatment of Diabetic Retinopathy | EUROCONDOR | participant | 5.998.762 | 18 |